2-nitro-4-(4-fluorophenyl)-fluorobenzene | 7602-93-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-nitro-4-(4-fluorophenyl)-fluorobenzene
• 英文别名: 4,4'-Difluoro-3'-nitrobiphenyl；1-fluoro-4-(4-fluorophenyl)-2-nitrobenzene
• CAS: 7602-93-9
• 化学式: C₁₂H₇F₂NO₂
• 分子量: 235.19
• InChiKey: YFFSYOSAAQNYSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-nitro-4-(4-fluorophenyl)-fluorobenzene 在 sodium methylate 、 碳酸氢钠 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of N-hydroxybenzimidazoles as potential anticancer agents targeting human lactate dehydrogenase A

  摘要：

  In this paper, a novel series of N-hydroxybenzimidazoles as potential anticancer agents were designed and synthesized. The in vitro enzymatic assays suggested N-hydroxy-6-(3-nitrophenyl)-benzimidazole-2-carboxylic acid had good inhibitory potency (IC50 = 0.25 mu M) to human lactate dehydrogenase A. Cytotoxic assay revealed that this compound gave the best potency (IC50 = 2.2 mu M) to inhibit BGC-823 cell proliferation. Furthermore, molecular docking study showed it had strong interactions with lactate dehydrogenase A, which was in line with our experimental results.

  DOI：

  10.1007/s00706-015-1513-9

文献信息

• Use of substituted 2 phenylbenzimidazoles as medicaments
  申请人：Streicher Ruediger

  公开号：US20050014810A1

  公开（公告）日：2005-01-20

  The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R 1 is a group of formula

  本发明涉及使用式I的取代2-苯基苯并咪唑，其中R1、R2、R3、R4、R5和m具有权利要求中给出的含义，用于制备治疗或预防涉及胰高血糖素受体疾病的药物，以及式I的新化合物，其中R1是一个公式的基团。
• Chiral aldehyde catalysis enables direct asymmetric α-substitution reaction of N-unprotected amino acids with halohydrocarbons
  作者：Hao-Ran Shen、Chao-Xing Li、Xin Jiang、Yao Lin、Jian-Hua Liu、Fang Zhu、Zhu-Lian Wu、Tian Cai、Wei Wen、Rong-Xing He、Qi-Xiang Guo

  DOI：10.1039/d3sc01294h

  日期：——

  a simple chiral BINOL-aldehyde catalyst or combining catalysts of a chiral aldehyde and Lewis acid ZnCl2, the asymmetric α-arylation, α-allylation, and α-benzylation of amino acid esters with the corresponding halohydrocarbons proceed smoothly, producing α,α-disubstituted α-amino acids in moderate-to-high yields and good-to-excellent enantioselectivities. The asymmetric α-arylation reaction can be applied

  容易获得的氨基酸与卤代烃的直接催化 α-烃基化是产生 α,α-二取代的非蛋白原性 α-氨基酸化合物的最直接的方法之一。然而，所有报告的方法都依赖于 N-保护的氨基酸作为起始材料。在此，我们报告了三种高效醛催化的 N-未保护氨基酸酯与芳基、烯丙基和苄基卤化物的直接 α-烃基化反应。通过推广简单的手性 BINOL-醛催化剂或结合手性醛和路易斯酸 ZnCl 2的催化剂，氨基酸酯与相应卤代烃的不对称α-芳基化、α-烯丙基化和α-苄基化反应顺利进行，以中等到高产率和良好到优异的对映选择性生产α,α-二取代的α-氨基酸. 该不对称α-芳基化反应可用于临床候选化合物(+)-AG-041R的形式合成。基于对照实验给出的结果，提出了三种反应模型来说明立体选择性控制结果。
• Synthesis and biological evaluation of N-hydroxybenzimidazoles as potential anticancer agents targeting human lactate dehydrogenase A
  作者：Wei Yue、Hu Wang

  DOI：10.1007/s00706-015-1513-9

  日期：2015.12

  In this paper, a novel series of N-hydroxybenzimidazoles as potential anticancer agents were designed and synthesized. The in vitro enzymatic assays suggested N-hydroxy-6-(3-nitrophenyl)-benzimidazole-2-carboxylic acid had good inhibitory potency (IC50 = 0.25 mu M) to human lactate dehydrogenase A. Cytotoxic assay revealed that this compound gave the best potency (IC50 = 2.2 mu M) to inhibit BGC-823 cell proliferation. Furthermore, molecular docking study showed it had strong interactions with lactate dehydrogenase A, which was in line with our experimental results.